Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

The company will pay $140.6 million to settle claims that it illegally exported products to China. Separately, Cadence posted higher revenue in the second quarter and boosted its full-year earnings ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Princeton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, ...

Shareholders in Wise, a rare U.K. tech success, voted in favor of moving its main stock listing to New York and extending dual-class shares by a decade. The company will begin with five potential ...